Swiss pharmaceutical giant enters the weight loss drug market! Roche acquires Carmot for $3.1 billion.
I'm PortAI, I can summarize articles.
Swiss pharmaceutical giant Roche has acquired weight loss drug developer Carmot Therapeutics for $3.1 billion, sparking competition in the global weight loss drug market. Roche will pay $2.7 billion as an initial payment, with the potential to pay up to an additional $400 million based on specific targets. Carmot's products include gut hormone candidate drugs for treating obesity in both diabetic and non-diabetic patients, with the most promising being CT-388, a GLP-1/GIP dual receptor agonist. Roche's goal is to make CT-388 the best obesity drug and compete with similar drugs from companies like Novo Nordisk and Eli Lilly.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments